Insider Transactions in Q2 2021 at Edwards Lifesciences Corp (EW)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 07
2021
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,433
+34.62%
|
-
|
|
May 07
2021
|
Huimin Wang CVP, Japan & Intercontinental |
SELL
Open market or private sale
|
Direct |
6,350
-6.21%
|
$577,850
$91.87 P/Share
|
|
May 07
2021
|
Huimin Wang CVP, Japan & Intercontinental |
BUY
Exercise of conversion of derivative security
|
Direct |
6,350
+5.85%
|
$133,350
$21.76 P/Share
|
|
May 07
2021
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
3,389
-9.87%
|
$308,399
$91.87 P/Share
|
|
May 07
2021
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
3,389
+8.99%
|
$74,558
$22.29 P/Share
|
|
May 07
2021
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
11,050
-9.01%
|
$1,016,600
$92.69 P/Share
|
|
May 07
2021
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
11,050
+14.74%
|
$232,050
$21.76 P/Share
|
|
May 05
2021
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+5.01%
|
-
|
|
May 05
2021
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+9.41%
|
-
|
|
May 05
2021
|
Martha H. Marsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+8.9%
|
-
|
|
May 05
2021
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+30.65%
|
-
|
|
May 05
2021
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+4.03%
|
-
|
|
May 05
2021
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,615
+50.0%
|
-
|
|
May 05
2021
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
30,000
+0.94%
|
-
|
|
May 05
2021
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
35,550
-13.47%
|
$3,270,600
$92.62 P/Share
|
|
May 05
2021
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
30,000
-18.7%
|
-
|
|
May 05
2021
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
65,550
+28.74%
|
$852,150
$13.98 P/Share
|
|
May 04
2021
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
3,225
+15.73%
|
-
|
|
May 04
2021
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
3,975
+11.38%
|
-
|
|
May 04
2021
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,100
+13.67%
|
-
|
|
May 04
2021
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+7.04%
|
-
|
|
May 04
2021
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
2,850
+1.96%
|
-
|
|
May 04
2021
|
Michael A Mussallem Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,425
+15.32%
|
-
|
|
May 04
2021
|
Huimin Wang CVP, Japan & Intercontinental |
BUY
Grant, award, or other acquisition
|
Direct |
2,475
+2.52%
|
-
|
|
May 04
2021
|
Larry L Wood Global President TAVR & Surg |
BUY
Grant, award, or other acquisition
|
Direct |
4,575
+1.23%
|
-
|
|
May 04
2021
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+10.71%
|
-
|
|
Apr 27
2021
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
114,205
+3.53%
|
-
|
|
Apr 27
2021
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
114,205
-54.07%
|
-
|
|
Apr 23
2021
|
Heisz Leslie Stone Director |
SELL
Open market or private sale
|
Direct |
6,707
-22.91%
|
$650,579
$97.52 P/Share
|
|
Apr 23
2021
|
Heisz Leslie Stone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.46%
|
$350,000
$35.68 P/Share
|
|
Apr 23
2021
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Open market or private sale
|
Indirect |
12,000
-37.03%
|
$1,164,000
$97.66 P/Share
|
|
Apr 22
2021
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
3,389
-11.16%
|
$318,566
$94.4 P/Share
|
|
Apr 22
2021
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
3,389
+10.04%
|
$74,558
$22.29 P/Share
|
|
Apr 12
2021
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
7,830
-2.11%
|
$665,550
$85.84 P/Share
|
|
Apr 12
2021
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
7,830
+2.06%
|
$274,050
$35.2 P/Share
|
|
Apr 09
2021
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
13,077
-21.12%
|
$1,098,468
$84.27 P/Share
|
|
Apr 09
2021
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
13,077
+17.44%
|
$170,001
$13.98 P/Share
|
|
Apr 08
2021
|
Huimin Wang CVP, Japan & Intercontinental |
SELL
Open market or private sale
|
Direct |
6,350
-6.36%
|
$533,400
$84.88 P/Share
|
|
Apr 08
2021
|
Huimin Wang CVP, Japan & Intercontinental |
BUY
Exercise of conversion of derivative security
|
Direct |
6,350
+5.98%
|
$133,350
$21.76 P/Share
|
|
Apr 08
2021
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
30,000
+0.99%
|
-
|
|
Apr 08
2021
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
68,550
-24.5%
|
$5,758,200
$84.45 P/Share
|
|
Apr 08
2021
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
30,000
-9.68%
|
-
|
|
Apr 08
2021
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
98,550
+24.14%
|
$1,281,150
$13.98 P/Share
|
|
Apr 01
2021
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Open market or private sale
|
Direct |
13,020
-8.53%
|
$1,080,660
$83.66 P/Share
|
|
Apr 01
2021
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
13,020
+7.86%
|
$169,260
$13.98 P/Share
|